Biogen raised to Overweight at Piper Sandler on Apellis buyout
Source: SeekingAlpha
2026-04-14 10:58:06 ET
More on Biogen, Apellis Pharmaceuticals
- Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease
- Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript
- Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives - Slideshow
- Apellis surges on $5.6B buyout deal with Biogen
- Biogen receives FDA approval for high-dose Spinraza regimen
Read the full article on Seeking Alpha
For further details see:
Biogen raised to Overweight at Piper Sandler on Apellis buyout
Apellis Pharmaceuticals Inc.
NASDAQ: APLS
APLS Trading
-0.01% G/L:
$41.04 Last:
5,223,027 Volume:
$41.05 Open:
APLS Latest News
May 07, 2026 06:01:00 pm
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
APLS Stock Data
$2,869,591,944
89,501,409
1.5%
87
N/A
Biotechnology & Life Sciences
Healthcare
US
Waltham
